Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
November 06, 2019 19:37 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento’s research team will...
Los Angeles Court Rejects Patrick Soon-Shiong’s Attempt to Avoid Sorrento Litigation Allowing Arbitration Case to Move Forward
October 15, 2019 22:36 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that a Los Angeles Superior Court judge has rejected Patrick Soon-Shiong’s attempt...
Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering
October 09, 2019 10:35 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...
Sorrento Therapeutics Announces $25 Million Registered Direct Offering
October 07, 2019 14:35 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...
Scilex Announces New Medicaid Agreements with CA & FL
October 01, 2019 07:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), is excited to announce that its...
Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak
September 30, 2019 07:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors...
Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
September 23, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has confidentially...
Sorrento Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Warrants
July 02, 2019 12:40 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, July 02, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...
Sorrento Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
June 28, 2019 08:37 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...
Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial
June 19, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
Forty five patients were treated with escalating doses of RTX in the Phase 1b trial to date. Thirty seven patients received RTX and eight patients received saline (pooled as placebo group).Most...